FDA Approves Nexus' Tranexamic Acid for Enhanced Wound Healing
Nexus Pharmaceuticals has received FDA approval for Tranexamic Acid in 0.7% Sodium Chloride Injection. This innovative product, set to hit the market soon, promises to enhance wound healing and reduce blood transfusion needs.
Tranexamic Acid in 0.7% Sodium Chloride, an intravenous antifibrinolytic, is designed for short-term use in hemophilia patients. It promotes healthy blood clotting, minimizing tissue damage and accelerating healing.
The product will be available in packs of ten 1,000 mg/100 mL IV bags. It can also provide pain control post-operatively or in injury cases. Nexus Pharmaceuticals, known for its innovative manufacturing processes, ensures high-quality drugs that meet critical unmet medical needs.
With the FDA approval, Nexus Pharmaceuticals expands its product line. Omair Ahmed, Chief Operating Officer, expressed excitement about this addition. Although the exact market release date is not yet public, the product is expected to provide dependable, life-saving treatment options for patients.
